Experimental cancer therapy using restoration of NAD+-linked 15-hydroxyprostaglandin dehydrogenase expression

Molecular Cancer Therapeutics

Volumn 8, Issue 11, 2009, Pages 3130-3139

  Kaliberova, Lyudmila N ^a   Kusmartsev, Sergei A ^f   Krendelchtchikova, Valentina ^b   Stockard, Cecil R ^c   Grizzle, William E ^c   Buchsbaum, Donald J ^d   Kaliberov, Sergey A ^e  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d The University of Alabama at Birmingham   (United States)

^e Kentucky   (United States)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ADENOVIRUS VECTOR; BEVACIZUMAB; CYCLOOXYGENASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROSTAGLANDIN E RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL MIGRATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; EXPERIMENTAL THERAPY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; CYCLOOXYGENASE 2; DINOPROSTONE; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70949096629     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-09-0270     Document Type: Article

References (47)

1. Hla T, Bishop-Bailey D, Liu CH, Schaefers HJ, Trifan OC. Cyclooxygenase- 1 and -2 isoenzymes. Int J Biochem Cell Biol 1999;31:551-557
2. O'Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 1993;330:156-160 (Pubitemid 23265121)
3. Boland GP, Butt IS, Prasad R, Knox WF, Bundred NJ. COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer 2004;90:423-429 (Pubitemid 38250640)
4. Ristimaki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62: 632-635 (Pubitemid 34126931)
5. Soumaoro LT, Uetake H, Higuchi T, Takagi Y, Enomoto M, Sugihara K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res 2004;10:8465-8471 (Pubitemid 40053411)
6. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A 2004;101:591-596 (Pubitemid 38084681)
7. Kawai N, Tsujii M, Tsuji S. Cyclooxygenases and colon cancer. Prostaglandins Other Lipid Mediat 2002;68-69:187-196
8. Ranger GS, Thomas V, Jewell A, Mokbel K. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 2004;24:2349-2351 (Pubitemid 39166317)
9. Fenwick SW, Toogood GJ, Lodge JP, Hull MA. The effect of the selective cyclooxygenase-2 inhibitor rofecoxib on human colorectal cancer liver metastases. Gastroenterology2003;125:716-729
10. Tachimori A, Yamada N, Amano R, Ohira M, Hirakawa K. Combination therapy of S-1 with selective cyclooxygenase-2 inhibitor for liver metastasis of colorectal carcinoma. Anticancer Res 2008;28:629-638 (Pubitemid 351578902)
11. Yao M, Kargman S, Lam EC, et al. Inhibition of cyclooxygenase-2 byrofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res 2003;63:586-592 (Pubitemid 36158135)
12. Misra S, Hascall VC, Berger FG, Markwald RR, Ghatak S. Hyaluronan, CD44, and cyclooxygenase-2 in colon cancer. Connect Tissue Res 2008; 49:219-224
13. Mazhar D, Ang R, Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006;94:346-350
14. Saji S, Hirose M, Toi M. Novel sensitizing agents: potential contribution of COX-2 inhibitor for endocrine therapyof breast cancer. Breast Cancer 2004;11:129-133
15. Atiqur Rahman M, Toi M. Anti-angiogenic therapyin breast cancer. Biomed Pharmacother 2003;57:463-470
16. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 2002;8:289-293 (Pubitemid 34250108)
17. Kage K, Fujita N, Oh-hara T, Ogata E, Fujita T, Tsuruo T. Basic fibroblast growth factor induces cyclooxygenase-2 expression in endothelial cells derived from bone. Biochem Biophys Res Commun 1999;254:259-263 (Pubitemid 29292050)
18. Sorscher SM. Biological therapyu pdate in colorectal cancer. Expert Opin Biol Ther 2007;7:509-519
19. Backlund MG, Mann JR, Holla VR, et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem 2005;280:3217-3223
20. Tai HH, Cho H, Tong M, Ding Y. NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and biological functions. Curr Pharm Des 2006; 12:955-962
21. Yan M, Rerko RM, Platzer P, et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-β-induced suppressor of human gastrointestinal cancers. Proc Natl Acad Sci U S A 2004;101: 17468-17473 (Pubitemid 39657428)
22. Banu A, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Sem Oncol 2004;31:22-29 (Pubitemid 38879411)
23. Harris RE, Beebe-Donk J, Alshafie GA. Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade: results of case control studies. Subcell Biochem 2007;42:193-212.
24. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-266 (Pubitemid 34196319)
25. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001;41:661-690
26. 2-mediated cAMP production during neuronal differentiation of human neuroblastoma SK-N-BE(2)C cells. J Neurochem 2001;79:303-310
27. 2 increases growth and motilityof colorectal carcinoma cells. J Biol Chem 2001;276:18075-18081
28. Mann JR, Backlund MG, Buchanan FG, et al. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res 2006; 66:6649-6656
29. Yang L, Amann JM, Kikuchi T, et al. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res 2007;67:5587-5593 (Pubitemid 46984987)
30. Wakimoto N, Wolf I, Yin D, et al. Nonsteroidal anti-inflammatorydrugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 2008;68:6978-6986
31. Gee JR, Montoya RG, Khaled HM, Sabichi AL, Grossman HB. Cytokeratin 20, AN43, PGDH, COX-2 expression in transitional and squamous cell carcinoma of the bladder. Urol Oncol 2003;21:266-270
32. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase- 1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56:5125-5127 (Pubitemid 26383023)
33. Wolf I, O'Kelly J, Rubinek T, et al. 15-hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res 2006; 66:7818-7823 (Pubitemid 44289243)
34. 2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem 2003;278:35451-35457
35. Ma X, Kundu N, Rifat S, Walser T, Fulton AM. Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis. Cancer Res 2006; 66:2923-2927
36. Mutoh M, Watanabe K, Kitamura T, et al. Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res 2002; 62:28-32.
37. Pozzi A, Yan X, Macias-Perez I, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem 2004;279:29797-29804 (Pubitemid 38915863)
38. 2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003;289:265-274
39. Wu Y, Hooper AT, Zhong Z, et al. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 2006;119:1519-1529 (Pubitemid 44258756)
40. Schmidt M, Voelker HU, Kapp M, Dietl J, Kammerer U. Expression of VEGFR-1 (Flt-1) in breast cancer is associated with VEGF expression and with node-negative tumour stage. Anticancer Res 2008;28: 1719-1724 (Pubitemid 351892949)
41. Weigand M, Hantel P, Kreienberg R, Waltenberger J. Autocrine vascular endothelial growth factor signalling in breast cancer. Evidence from cell lines and primaryb reast cancer cultures in vitro. Angiogenesis 2005;8: 197-204.
42. Ghosh S, Sullivan CA, Zerkowski MP, et al. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin- 1) are associated with worse outcome in breast cancer. Hum Pathol 2008;39: 1835-1843.
43. Fan F, Wey JS, McCarty MF, et al. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene 2005;24:2647-2653 (Pubitemid 40593092)
44. Kaliberov SA, Kaliberova L, Stockard CR, Grizzle WE, Buchsbaum DJ. Adenovirus-mediated flt-1 targeted proapoptotic gene therapy of human prostate cancer. Mol Ther 2004;10:1059-1070 (Pubitemid 39625250)
45. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581-611. (Pubitemid 39099316)
46. Kusmartsev S, Eruslanov E, Kubler H, et al. Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinoma. J Immunol 2008;181:346-353
47. Eruslanov E, Kaliberov S, Daurkin I, et al. Altered expression of 15- hydroxyprostaglandin dehydrogenase in tumor-infilatrated CD11b myeloid cells: a mechanism for immune evasion in cancer. J Immunol 2009;182: 7548-7557